Rituximab-containing Chemotherapy (R-CHOP)-induced Kaposi's Sarcoma in an HIV-negative Patient with Diffuse Large B Cell Lymphoma
-
- Ureshino Hiroshi
- Department of Internal Medicine, Karatsu Red Cross Hospital, Japan
-
- Ando Toshihiko
- Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan
-
- Kojima Kensuke
- Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan
-
- Itamura Hidekazu
- Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan
-
- Jinnai Shunichi
- Department of Dermatology, Karatsu Red Cross Hospital, Japan
-
- Doi Kazuko
- Department of Dermatology, Karatsu Red Cross Hospital, Japan
-
- Ohshima Koichi
- Department of Pathology, School of Medicine, Kurume University, Japan
-
- Kurogi Kazuya
- Department of Internal Medicine, Karatsu Red Cross Hospital, Japan
-
- Miyahara Masaharu
- Department of Internal Medicine, Karatsu Red Cross Hospital, Japan
-
- Kimura Shinya
- Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan
書誌事項
- 公開日
- 2015
- 資源種別
- journal article
- DOI
-
- 10.2169/internalmedicine.54.5103
- 公開者
- 一般社団法人 日本内科学会
この論文をさがす
説明
Rituximab treatment may cause or exacerbate Kaposi's sarcoma (KS) in patients with human immunodeficiency virus (HIV)-associated multicentric Castleman's disease. Despite the widespread use of rituximab, rituximab-induced KS has not yet been reported in HIV-negative patients with diffuse large B cell lymphoma (DLBCL). We herein report a case of KS that developed after undergoing rituximab-containing chemotherapy in an HIV-negative patient with DLBCL. An 84-year-old man who received rituximab-containing chemotherapy for the treatment of DLBCL developed severe infection, and subsequently KS. Our observations indicate that serious infections under rituximab treatment may trigger KS. KS should therefore be considered when skin tumors appear in lymphoma patients receiving rituximab-containing chemotherapy.<br>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 54 (24), 3205-3208, 2015
一般社団法人 日本内科学会